The M&A and Life Sciences teams advised Forma Therapeutics, Holdings Inc. on its acquisition by Novo Nordisk. 

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. Etavopivat, Forma Therapeutics’ lead development candidate, is an investigational oral, once-daily, selective pyruvate kinase-R (PKR) activator being developed to improve anemia and red blood cell health in people with SCD, a seriously debilitating, life-threatening and life shortening disease.

Novo Nordisk acquired all outstanding shares of common stock of Forma at a price of $20 per share in cash. At the completion of the merger, Forma became a wholly owned subsidiary of Novo Nordisk. The common stock of Forma will no longer be listed or traded on the Nasdaq Global Select Market.

The Goodwin team consisted of Stuart CableLisa HaddadAndrew GoodmanTevia PollardCynthia (Xiaoyue) LiStephanie BarbanellWilliam CollinsGabriela Morales-RiveraKathryn Clerici and Kimberly Rodriguez (Corporate); Monica PatelAdrean Taylor and Chris Jones (ERISA & Executive Compensation); Jennifer Fay (Employment); Janet AndolinaCaroline Bullerjahn and Viktors Dindzans (Litigation); Arman OrucCharlie Stewart and Simone Waterbury (Antitrust); Roger Cohen and Heath Ingram (Healthcare); Susan LeeCatherine McCarty (Intellectual Property); Chris Denn (Licensing); Jacqueline Klosek and Paul Thompson (Privacy); and Richard Matheny.

For more details, read the press release.